PACAP-38 vs GPE
Head-to-head comparison of PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38)) and GPE (Glycyl-L-prolyl-L-glutamic acid) — benefits, dosing, side effects, research data, and where to buy.
| Property | PACAP-38 | GPE |
|---|---|---|
| Category | Cognitive Enhancement | Cognitive Enhancement |
| Full Name | Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38) | Glycyl-L-prolyl-L-glutamic acid |
| Molecular Weight | 4534 Da | 301.30 Da |
| Half-Life | minutes | minutes |
| Amino Acids | 38 aa | 3 |
| Typical Dose | 10-100 µg preclinical range | 0.1-10 mg/kg preclinical |
| Route | Intranasal | Intranasal/Intracerebroventricular |
| Purity | ≥98% | ≥98% |
| Studies Count | 650 | 25 |
| Research Status | Pre-clinical | Pre-clinical |
PACAP-38 Benefits
- ✓synaptic plasticity
- ✓BDNF upregulation
- ✓neuroprotection
- ✓memory consolidation
GPE Benefits
- ✓memory consolidation
- ✓neuroprotection
- ✓synaptic plasticity
- ✓learning support
PACAP-38 Dosing
0.1-1 nmol ICV in rodents|10-100 µg intranasal in preclinical studies|single-dose or short repeated protocols
GPE Dosing
intranasal or ICV research doses|0.1-10 mg/kg preclinical range|repeat daily or intermittent protocols
PACAP-38 Side Effects
- ⚠headache-like effects
- ⚠flushing
- ⚠hypotension
GPE Side Effects
- ⚠limited human safety data
- ⚠short half-life
- ⚠local irritation with nasal delivery
Research Overview
PACAP-38
PACAP-38 is one of the most studied endogenous neuropeptides for protecting neurons from ischemic and excitotoxic damage. Preclinical literature also links it to hippocampal plasticity and learning-related signaling, including increased BDNF expression.
GPE
Preclinical studies suggest GPE can reduce neuronal damage and support plasticity-related pathways in the brain. Research interest centers on hippocampal function, which links it to learning and memory paradigms.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.